Fluorescent SN38 Precursor for Solubility and Tumor Tracking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
7-Ethyl-10-hydroxycamptothecin (SN38) suffers from poor solubility, instability, and low bioavailability, limiting its clinical use, while current prodrugs like irinotecan (CPT-11) have low conversion efficiency into SN38, and there is a need for improved tumor diagnosis and treatment monitoring.
Innovation Solution
A 7-ethyl-10-hydroxycamptothecin drug precursor (BDP-SN38) is synthesized by condensing a boron dipyrromethene dye molecule (BODIPY) with the hydroxyl group of SN38, enhancing solubility, stability, and fluorescence, allowing for real-time tumor tracking and synergistic chemotherapy-phototherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SN38 is used as an anticancer drug, then antitumor activity is achieved, but solubility and stability are poor
Solution Approach 1:
The patent segments the SN38 molecule by protecting the unstable lactone ring through formation of a cyclic carbonate derivative. This segmentation isolates the unstable lactone moiety and replaces it with a more stable cyclic carbonate structure, thereby improving overall molecular stability while preserving the antitumor activity of the camptothecin core structure.
Solution Approach 2:
The patent creates a composite structure by combining SN38 with a cyclic carbonate group formed from reaction with carbon dioxide. This composite material integrates the antitumor pharmacophore of SN38 with the stabilizing effect of the cyclic carbonate derivative, achieving both therapeutic activity and improved stability.
2Quantity of substance
If CPT-11 is used as a prodrug to improve solubility, then solubility is enhanced, but conversion efficiency to SN38 is low (only 2-8%)
Solution Approach 1:
The patent introduces a cyclic carbonate derivative as an intermediate structure that facilitates better solubility while maintaining high conversion efficiency to SN38. This intermediary structure serves as a bridge between the need for improved solubility and the requirement for efficient conversion to the active drug, overcoming the limitations of conventional prodrugs like CPT-11.
3Measurement precision
If fluorescence imaging is used for tumor monitoring, then real-time detection capability is achieved, but additional complex procedures are required
Solution Approach 1:
The patent merges the anticancer drug function with fluorescence imaging capability by incorporating a fluorescent group into the cyclic carbonate derivative structure. This combination allows the single molecule to serve dual purposes: delivering antitumor activity and providing real-time fluorescence imaging for tumor monitoring, thereby eliminating the need for separate imaging procedures and reducing overall procedural complexity.
Solution Approach 2:
The patent creates a universal compound that performs multiple functions simultaneously: the cyclic carbonate derivative with integrated fluorescent group acts as both an anticancer agent and a fluorescent probe. This multi-functional molecule can deliver therapeutic effects while enabling real-time imaging, monitoring, and tracking of tumor cells throughout the treatment process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BDP-SN38 exhibits comparable antitumor activity to SN38, high tumor uptake, and strong fluorescence, enabling effective tumor tracking and enhanced treatment efficacy through combined therapies.
Implementation Method 1
BDP-SN38 exhibits comparable antitumor activity, has high tumor uptake capacity, and produces strong green fluorescence with the excitation of visible light
Data Source
AI summary
The invention provides a 7-ethyl-10-hydroxycamptothecin drug precursor with fluorescence activity and a preparation method and use thereof. The method involves that a carboxyl group of a boron dipyrromethene dye molecule is condensed with a hydroxyl group at the 10 position of 7-ethyl-10-hydroxycamptothecin, yielding a 7-ethyl-10-hydroxy-camptothecin drug precursor (BDP-SN38) with fluorescent activity. BDP-SN38 shows good solubility and stability in most pharmaceutically acceptable solvents. Compared with SN38, BDP-SN38 exhibits comparable antitumor activity, has high tumor uptake capacity, and produces strong green fluorescence with the excitation of visible light, thus providing fluorescence-guided bioimaging and further treatment of residual tumors after drug treatment, and having good application prospects in the research of integrated diagnosis and treatment and effective tumor treatment.